The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

T. Durant, Stephen; Zheng, Li; Wang, Yingchun; Chen, Kan; Zhang, Lingli; Zhang, Tianwei; Yang, Zhenfan; C. Riches, Lucy; G. Trinidad, Antonio; H. L. Fok, Jacqueline; A. Hunt, Thomas; G. Pike, Kurt; Wilson, Joanne; Smith, Aaron; Colclough, Nicola; Pilla Reddy, Venkatesh; Sykes, Andrew; Janefeldt, Annika; Johnström, Peter; Varnäs, Katarina; Takano, Akihiro; Ling, Stephanie; P. Orme, Jonathan; Stott, Jonathan; G.P. ROBERTS, CAROLINE; P. Barrett, Ian; N. Jones, Gemma; P. Roudier, Martine; Pierce, Andrew; Allen, Jasmine; Kahn, Jenna; Sule, Amrita; Karlin, Jeremy; Cronin, Anna; Chapman, Melissa; Valerie, Kristoffer; Illingworth, Ruth; Pass, Martin

doi:10.1126/sciadv.aat1719

Public

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Published in Science Advances • Jun 1, 2018

Authors:

Stephen T. Durant

Li Zheng

Yingchun Wang

Abstract

cell cycle phase accumulation, micronuclei, and apoptosis. AZD1390 radiosensitizes glioma and lung cancer cell lines, with p53 mutant glioma cells generally being more radiosensitized than wild type. In in vivo syngeneic and patient-derived glioma as well as orthotopic lung-brain metastatic models, ...

Subject

Cancer research

Glioma

Brain tumor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!